CA3001231C - Antibody against hepatitis b surface antigen and use thereof - Google Patents

Antibody against hepatitis b surface antigen and use thereof Download PDF

Info

Publication number
CA3001231C
CA3001231C CA3001231A CA3001231A CA3001231C CA 3001231 C CA3001231 C CA 3001231C CA 3001231 A CA3001231 A CA 3001231A CA 3001231 A CA3001231 A CA 3001231A CA 3001231 C CA3001231 C CA 3001231C
Authority
CA
Canada
Prior art keywords
seq
set forth
antibody
antigen binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3001231A
Other languages
English (en)
French (fr)
Other versions
CA3001231A1 (en
Inventor
Wenxin Luo
Bing Zhou
Juan Zhang
Quan Yuan
Tianying ZHANG
Jun Zhang
Ningshao Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Sheng Tang Co Ltd
Xiamen University
Original Assignee
Yang Sheng Tang Co Ltd
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd, Xiamen University filed Critical Yang Sheng Tang Co Ltd
Publication of CA3001231A1 publication Critical patent/CA3001231A1/en
Application granted granted Critical
Publication of CA3001231C publication Critical patent/CA3001231C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3001231A 2015-10-09 2016-10-09 Antibody against hepatitis b surface antigen and use thereof Active CA3001231C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510647977.7 2015-10-09
CN201510647977 2015-10-09
PCT/CN2016/101560 WO2017059813A1 (zh) 2015-10-09 2016-10-09 抗乙肝表面抗原的抗体及其用途

Publications (2)

Publication Number Publication Date
CA3001231A1 CA3001231A1 (en) 2017-04-13
CA3001231C true CA3001231C (en) 2022-07-12

Family

ID=58487306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3001231A Active CA3001231C (en) 2015-10-09 2016-10-09 Antibody against hepatitis b surface antigen and use thereof

Country Status (10)

Country Link
US (1) US10689434B2 (https=)
EP (1) EP3360896B1 (https=)
JP (2) JP6949012B2 (https=)
KR (1) KR102132604B1 (https=)
CN (1) CN106565840B (https=)
AU (1) AU2016334290B2 (https=)
BR (1) BR112018007121A2 (https=)
CA (1) CA3001231C (https=)
ES (1) ES3041684T3 (https=)
WO (1) WO2017059813A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6949012B2 (ja) * 2015-10-09 2021-10-13 シャアメン ユニバーシティ Ｂ型肝炎表面抗原に対する抗体及びその使用
EP3801766A1 (en) * 2018-05-31 2021-04-14 Novartis AG Hepatitis b antibodies
BR112020021266A2 (pt) * 2018-05-31 2021-01-26 Daiichi Sankyo Company, Limited anticorpo anti-tlr7 humano
JP7454855B2 (ja) * 2018-12-21 2024-03-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
CN111978393B (zh) * 2019-05-23 2024-06-18 厦门大学 抗乙肝病毒新型抗体及其用途
CN111242107B (zh) * 2020-04-26 2021-03-09 北京外号信息技术有限公司 用于设置空间中的虚拟对象的方法和电子设备
PE20240080A1 (es) * 2020-06-08 2024-01-16 Hoffmann La Roche Anticuerpos anti-hbv y metodos de uso
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1395617A (zh) 2000-10-02 2003-02-05 韩国生命工学研究院 抗乙肝病毒表面抗原s的人源化抗体及其制备方法
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
EP2250198B1 (en) * 2008-01-23 2016-03-09 Department of Biotechnology A humanized high affinity recombinant antibody against hepatitis b surface antigen
KR101072895B1 (ko) 2009-12-24 2011-10-17 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체
CN102786592A (zh) 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
EP3308798B1 (en) 2012-06-11 2020-09-09 Xiamen University Polypeptides and antibodies for treating hbv infection and related diseases
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
US10167333B2 (en) 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
JP6949012B2 (ja) * 2015-10-09 2021-10-13 シャアメン ユニバーシティ Ｂ型肝炎表面抗原に対する抗体及びその使用

Also Published As

Publication number Publication date
WO2017059813A1 (zh) 2017-04-13
JP2021063092A (ja) 2021-04-22
CN106565840B (zh) 2020-09-01
JP2018533937A (ja) 2018-11-22
US20190389939A1 (en) 2019-12-26
JP6949012B2 (ja) 2021-10-13
ES3041684T3 (en) 2025-11-13
AU2016334290B2 (en) 2020-06-18
AU2016334290A1 (en) 2018-05-10
US10689434B2 (en) 2020-06-23
CA3001231A1 (en) 2017-04-13
BR112018007121A2 (pt) 2018-11-06
EP3360896B1 (en) 2025-07-23
EP3360896A4 (en) 2019-08-28
CN106565840A (zh) 2017-04-19
KR20180084045A (ko) 2018-07-24
EP3360896A1 (en) 2018-08-15
KR102132604B1 (ko) 2020-07-13

Similar Documents

Publication Publication Date Title
CA3001231C (en) Antibody against hepatitis b surface antigen and use thereof
US12447208B2 (en) Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses
KR20210005169A (ko) 최적화된 항tl1a 항체
HK1247214B (zh) 一种pdl-1抗体、其药物组合物及其用途
RU2765878C2 (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
CN115087673A (zh) 结合il4r的抗体及其用途
US20250368722A1 (en) Multispecific antibodies targeting multiple epitopes on the hiv-1 envelope
JP7490574B2 (ja) Ｂ型肝炎抗体
TWI721457B (zh) 全人源的抗lag-3抗體及其應用
JP2023543826A (ja) 抗ｃｄ３抗体およびその使用
JP2022507599A (ja) 安定性が向上した抗ｃ－ｍｅｔ抗体又はその抗原結合断片
CN113549146B (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
WO2024123897A1 (en) Broadly neutralizing and potent antibodies against hiv
HK40079597A (en) Antibodies binding il4r and uses thereof
KR20260019469A (ko) 만성 D형 간염의 치료를 위한 항-HBsAg 항체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181018

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240828

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240828

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240828

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250821